Carsten Rudolph
Managing Director & Chief Executive Officer Ethris
Carsten Rudolph, PhD is a co-founder of Ethris and the lead inventor of its SNIM® RNA Technology. His deep expertise is delivering mRNA specifically to the lungs. He is the inventor of 15 patents/applications and has authored more than 120 scientific publications. Carsten is affiliated with the Dr. von Haunersche Children’s Hospital, part of Ludwig Maximilian University in Munich. He obtained his pharmaceutical degree from the Freie Universität Berlin.
Seminars
Tuesday 21st July 2026
CEO & mRNA Leaders Think Tank: From CAR-T Platforms, Gene Editing Triumphs & Cancer Immunotherapy Clinical Advances; Navigating mRNA’s Potential into New Therapies & Tools Towards Better Drugs for Patients Faster
9:00 am
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
Wednesday 22nd July 2026
Development of mRNA Therapeutics for the Prevention & Treatment of Respiratory Diseases
1:30 pm
- Clinical update on ETH47 – a first-in-class mRNA-based nasal spray treatment for uncontrolled asthma
- ETH47 encodes interferon lambda (IFNλ), aiming to boost innate immune defense in the airways and address viral triggers of asthma exacerbations
- Development of spray-dried mRNA for formulation for respiratory tract delivery
- Next generation mucosal mRNA vaccines for transmission blocking
